USP Standard for Dissolution Testing withdrawn
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In a notice from 20 December 2011 the United States Pharmacopeia (USP) has notified that Chlorpheniramine Maleate Extended-Release Tablets RS will be withdrawn as of 1 February 2012.
These tablets had been used for testing the Performance Verification Suitability according to the General Chapter <711> for Apparatus 3.
This withdrawal is due to the fact that no suitable replacement candidate has been found to date.
USP remains convinced that a Performance Verification Test is a critical element in the qualification of dissolution apparatuses.
During the ECA Conference "Dissolution Testing - Development - Quality Control - and in vivo Relevance" taking place from 17-19 October 2012 in Berlin, the newest USP requirements concerning the qualification of apparatuses will be presented and compared to the FDA requirements on mechanical qualification.
Please also read USP's complete notice.
Author:
Dr. Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
15.12.2025FDA Warning Letter Criticises Handling of OOS Results at a Contract Laboratory
15.12.2025FDA Warning: No Recall Conducted Despite Confirmed Benzene Impurity
10.12.2025FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations
26.11.2025FDA Warning Letter Highlights Deficiencies in SST and HPLC Practices
13.11.2025Proposed Revision of USP <1225> Published in the Pharmacopeial Forum